Related Experiment Video

Updated: Dec 14, 2025

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea
07:36

Analysis of Raw and Processed Cyperi Rhizoma Samples Using Liquid Chromatography-Tandem Mass Spectrometry in Rats with Primary Dysmenorrhea

Published on: December 23, 2022

1.8K

Non-steroidal anti-inflammatory drugs, prostaglandins, and COVID-19

Calum T Robb1, Marie Goepp1, Adriano G Rossi1

  • 1Centre for Inflammation Research, Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.

British Journal of Pharmacology
|July 24, 2020
PubMed

Insights

Non-steroidal anti-inflammatory drugs (NSAIDs) may impact COVID-19 progression by affecting prostaglandins (PGs). This review explores the potential roles of NSAIDs and PGs in SARS-CoV-2 infection and disease development.

Area of Science:

  • Pharmacology
  • Virology
  • Immunology

Background:

  • COVID-19, caused by SARS-CoV-2, is a global pandemic with no current vaccine or efficient treatment.
  • Common COVID-19 symptoms include fever, pain, and inflammation.
  • Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used to manage these symptoms by inhibiting prostaglandin (PG) production.

Purpose of the Study:

  • To review the potential roles of NSAIDs in SARS-CoV-2 infection.
  • To survey the potential roles of prostaglandins (PGs) during COVID-19 progression.
  • To understand the complex interactions between NSAIDs, PGs, and SARS-CoV-2.

Main Methods:

  • Literature review of existing studies on NSAIDs, prostaglandins, and SARS-CoV-2.
  • Analysis of the mechanisms by which NSAIDs affect prostaglandin synthesis.
  • Examination of the dual role of prostaglandins (pro-inflammatory and anti-inflammatory) in infectious diseases.

Main Results:

  • NSAIDs block prostaglandin production, which can alleviate COVID-19 symptoms.
  • Prostaglandins have complex roles, potentially influencing both the severity and resolution of SARS-CoV-2 infection.
  • The net effect of NSAIDs on COVID-19 outcomes requires further investigation due to the dual nature of PGs.

Conclusions:

  • NSAIDs and prostaglandins may significantly influence the course of COVID-19.
  • Understanding these interactions is crucial for developing effective therapeutic strategies.
  • Further research is needed to elucidate the precise impact of NSAIDs on SARS-CoV-2 infection and COVID-19 pathogenesis.
Keywords:
COVID-19NSAIDSARS-CoV-2cytokine storminflammationprostaglandin

More Related Videos

Prostaglandin Extraction and Analysis in Caenorhabditis elegans08:50

Prostaglandin Extraction and Analysis in Caenorhabditis elegans

Published on: June 25, 2013

20.0K
Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response12:50

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response

Published on: September 15, 2017

6.8K

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
920
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
350
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
928
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.2K
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
892
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
991